Education
About Us
Working with TipRanks
Follow Us
ACADIA Pharmaceuticals Inc. (ACAD)
:ACAD
Total Valuation
ACADIA Pharmaceuticals has a market cap or net worth of $2.43B. The enterprise value is $2.35B.
Market Cap$2.43B
Enterprise Value$2.35B
Share Statistics
ACADIA Pharmaceuticals has 166.79M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding166.79M
Owned by Insiders24.05%
Owned by Instutions0.31%
Financial Efficiency
ACADIA Pharmaceuticals’s return on equity (ROE) is 0.31 and return on invested capital (ROIC) is 25.22%.
Return on Equity (ROE)30.90%
Return on Assets (ROA)19.07%
Return on Invested Capital (ROIC)25.22%
Return on Capital Employed (ROCE)29.11%
Revenue Per Employee$1,466,764.165
Profits Per Employee$346,785.605
Employee Count653
Asset Turnover0.81
Inventory Turnover3.73
Valuation Ratios
The current PE Ratio of ACADIA Pharmaceuticals is 13.43. ACADIA Pharmaceuticals’s PEG ratio is -0.03.
PE Ratio13.43
PS Ratio3.17
PB Ratio4.15
Price to Fair Value4.15
Price to FCF19.34
Price to Operating Cash Flow19.28
PEG Ratio-0.03
Income Statement
In the last 12 months, ACADIA Pharmaceuticals had revenue of $957.80M and earned $226.45M in profits. Earnings per share was $1.37.
Revenue$957.80M
Gross Profit$875.96M
Operating Income$230.79M
Pretax Income$258.07M
Net Income$226.45M
EBITDA97.59M
Earnings Per Share (EPS)1.37
Cash Flow
In the last 12 months, operating cash flow was $157.72M and capital expenditures -$523.00K, giving a free cash flow of $157.20M billion.
Operating Cash Flow$157.72M
Free Cash Flow$157.20M
Free Cash Flow per Share$0.94
Dividends & Yields
ACADIA Pharmaceuticals pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield5.17%
Earnings Yield7.45%
Stock Price Statistics
Beta1.16
52-Week Price Change-13.68%
50-Day Moving Average17.71
200-Day Moving Average16.88
Relative Strength Index (RSI)34.60
Average Volume (3m)1.78M
Important Dates
ACADIA Pharmaceuticals upcoming earnings date is May 13, 2025, After Close.
Last Earnings DateFeb 26, 2025
Next Earnings DateMay 13, 2025
Ex-Dividend Date―
Financial Position
ACADIA Pharmaceuticals as a current ratio of 2.38, with Debt / Equity ratio of 0.07
Current Ratio2.38
Quick Ratio2.32
Debt to Market Cap0.01
Net Debt to EBITDA-2.67
Interest Coverage Ratio0.00
Taxes
In the past 12 months, ACADIA Pharmaceuticals has paid $31.62M in taxes.
Income Tax$31.62M
Effective Tax Rate12.25%
Enterprise Valuation
ACADIA Pharmaceuticals EV to EBITDA ratio is 27.69, with an EV/FCF ratio of 17.64.
EV to Sales2.90
EV to EBITDA27.69
EV to Free Cash Flow17.64
EV to Operating Cash Flow17.58
Balance Sheet
ACADIA Pharmaceuticals has $755.99M in cash and marketable securities with $51.99M in debt, giving a net cash position of -$704.00M billion.
Cash & Marketable Securities$755.99M
Total Debt$51.99M
Net Cash-$704.00M
Net Cash Per Share-$4.22
Tangible Book Value Per Share$3.70
Margins
Gross margin is 91.46%, with operating margin of 24.10%, and net profit margin of 23.64%.
Gross Margin91.46%
Operating Margin24.10%
Pretax Margin26.94%
Net Profit Margin23.64%
EBITDA Margin10.46%
EBIT Margin8.80%
Analyst Forecast
The average price target for ACADIA Pharmaceuticals is $26.14, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$26.14
Price Target Upside79.29%
Analyst ConsensusModerate Buy
Analyst Count15
Revenue Growth Forecast31.85%
EPS Growth Forecast